We have an exciting opportunity for a Fractional Chief Medical Officer with our partner, a clinical-stage biotechnology company developing therapies for rare diseases. The immediate focus will be on the company's lead program in the ophthalmology space.

You'll have the opportunity to champion the Phase 3 protocol through the company's next FDA meeting. You'll lead Phase 3 trial design and execution in multiple countries. You'll run the CRO selection process, finalize trial design, and lead site selection. Additionally, you'll provide clinical and regulatory credibility in investor conversations through the company's next funding round, alongside the founder and CEO.